Challenging Cases in Asthma: Optimizing Biologics in Adults (2 of 3)

Program Overview

You have a middle-aged patient with severe, steroid-dependent asthma, multiple atopic comorbidities, and who has failed biologic after biologic for asthma. What do you do? Listen to what this expert, interprofessional panel recommends for collaborative care team management of this case and others that learners have submitted for their discussion.

0.25 CE Credit(s)

Expires: August 29, 2023

Target Audience

Allergy/immunology and pulmonology clinicians engaged in the care of patients with asthma.

Educational Objectives

Upon successful completion of this educational activity, participants should be better able to:

Select an appropriate biologic therapy for patients with asthma based on disease severity and phenotype
Integrate the unique roles of the interprofessional care team in the management of comorbidity and quality of life issues in patients with severe and difficult-to-treat asthma

Activity Faculty

Michael E. Wechsler, MD, MMSc

Professor, Medicine
Director, Cohen Family NJH Asthma Institute
Associate Vice President, Innovation and Industry Relations
Division of Pulmonary, Critical Care and Sleep Medicine
National Jewish Health
Denver, CO

David M. Lang, MD

Professor, Medicine
Cleveland Clinic Lerner College of Medicine
Chair, Department of Allergy and Clinical Immunology
Respiratory Institute, Cleveland Clinic
Cleveland, OH

Rachel DeCosta, MSN, FNP-C

Family Nurse Practitioner
Division of Pulmonary, Critical Care & Sleep Medicine
Department of Medicine
National Jewish Health
Denver, CO

Provider Statement

This activity is provided by RMEI Medical Education, LLC

Supporter Statement

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.

Featured RMEI CE Activities

Challenging Cases in Asthma: Optimizing Biologics in Adults (2 of 3)

Program Overview

Target Audience

Educational Objectives

Activity Faculty

Michael E. Wechsler, MD, MMSc

David M. Lang, MD

Rachel DeCosta, MSN, FNP-C

Provider Statement

Supporter Statement

Quelling the Vicious Vortex: Targeting Neutrophil Serine Proteases in Non-Cystic Fibrosis Bronchiectasis

Navigating the Frontier of Hematologic Malignancy Therapies. Series of 5 Modules

Cell-Free DNA Potential in Guiding Therapies and Q&A – Module 5

PROTACs: A Paradigm Shift in Drug Discovery – Module 3

Join Our Network

Company

CE Accreditation

HIPAA Verified & Compliant

Subscribe